Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy

被引：0

|

作者：

Fulcher, Greg

Matthews, David

Perkovic, Vlado

Mahaffey, Kenneth W.

Weiss, Robert

Rosenstock, Julio

Capuano, George

Desai, Mehul

Shaw, Wayne

Vercruysse, Frank

Meininger, Gary

Neal, Bruce

机构：

来源：

DIABETES | 2013年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1124-P

引用

收藏

页码：A292 / A292

页数：1

相关论文

共 50 条

[41] ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Diels, J.
Schubert, A.
Hamilton, G.
Canovatchel, W.
VALUE IN HEALTH, 2015, 18 (07) : A598 - A598
[42] WEIGHT- AND HEALTH-RELATED QUALITY OF LIFE (WRQOL AND HRQOL) WITH CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (T2DM) ON BACKGROUND METFORMIN
Traina, S. B.
Ho, K. F.
VALUE IN HEALTH, 2013, 16 (07) : A448 - A448
[43] Canagliflozin (CANA) Improves Glycemic Control and Reduces Glycemic Variability in Patients with Type 1 Diabetes Mellitus (T1DM) Inadequately Controlled with Insulin
Rodbard, Helena W.
Peters, Anne L.
Cao, Anjun
Alba, Maria
DIABETES, 2016, 65 : A76 - A76
[44] Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4
Pilon, Dominic
Durkin, Michael
Manceur, Ameur
Ghelerter, Isabelle
Lafeuille, Marie-Hel
Lefebvre, Patrick
DIABETES, 2020, 69
[45] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
Thompson, G.
Schroeder, M.
Neslusan, C.
Willis, M.
Johansen, P.
Teschemaker, A.
DIABETOLOGIA, 2014, 57 : S330 - S330
[46] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
Martin, Silas
Neslusan, Cheryl
Vo, Lien
Teschemaker, Anna
Johansen, Pierre
Willis, Michael
DIABETES, 2014, 63 : A310 - A310
[47] Insulin glargine (GLAR) improves health related quality of life (HRQOL) in patients with type 2 diabetes (T2DM) inadequately controlled on sulfonylurea plus metformin (SU plus MET)
Vinik, AI
Dailey, G
Zhang, Q
DIABETES, 2005, 54 : A142 - A142
[48] Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
Luo, Jian-Quan
Shu, Yan
Zhang, Wei
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[49] Vascular responsiveness in type 2 diabetes mellitus (T2DM)
Blum, A.
Socea, D.
Sirchan, R.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (12) : 791 - 796
[50] The platelets characteristics in type 2 diabetes mellitus (T2DM)
Buryachkovskaya, L.
Uchitel, I. A.
Sumarokov, A. B.
Docenko, U., V
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931

← 1 2 3 4 5 →